Kyverna Therapeutics KYTX
NASDAQ KYTX
$5.73 -0.11 (-1.88%)
At close: Oct 22, 2026 · 4:00 PM EDT

Kyverna Therapeutics (KYTX) Ending Cash Balance (2023 - 2025)

Updated

Analysis

Kyverna Therapeutics (KYTX) Ending Cash Balance (2023 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Ending Cash Balance (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn 8.95 Bn
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn 16.91 Bn
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn 6.57 Bn
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn 6.89 Bn
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn 7.62 Bn
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn 4.88 Bn
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn 13.99 Bn
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn 3.18 Bn
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn 1.03 Bn
10 Kyverna Therapeutics 352.80 Mn -533.58 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 124.64 Mn
Dec 31, 2024 97.17 Mn
Dec 31, 2023 35.21 Mn
API Access

Kyverna Therapeutics Ending Cash Balance API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ending-cash-balance&ticker=KYTX&period=max&api_key=YOUR_API_KEY